July 23, 2024
View Full PaperFigure 3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Key Points
Key points are not available for this paper at this time.
Abstract
Best percentage change in tumor size in all evaluable patients in cohort A (Other Solid Tumors) and cohort B (ccRCC).